07/10/24 09:03:15 0opcXuwt
リタリン：科学的には欝への効果は無い。
↓は症例数もまぁまぁ。治療抵抗性の欝にリタリンを併用したが、効果が無かったという報告。評価は４週間で行われた。
A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression
.
Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P.
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27704, USA. ashwin.patkar@duke.edu
We examined the efficacy and tolerability of augmentation with an extended release formulation of methylphenidate (OROS MPH, Concerta)
in patients with major depression who were nonresponders or partial responders to antidepressants. Sixty subjects with treatment-resistant
depression (TRD) participated in a 4-week, randomized, double-blind, placebo-controlled study of augmentation with methylphenidate (18-54 mg/d).
The preexisting antidepressant dose was unchanged. The primary efficacy measure was change in the 21-item Hamilton Depression Rating Scale
from randomization to end of treatment. Data were analyzed with intent-to-treat with last observation carried forward approach. There were no
statistically significant differences between the methylphenidate (n = 30) and placebo (n = 30) groups in reduction in 21-item Hamilton Depression